Trial Profile
A Multicenter, Double-Blinded, Randomized, Placebo Controlled Study to Investigate the Safety and Immunogenicity of VAX102 When Given in the Same Arm With the Standard Influenza Vaccine in Healthy Adults.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2014
Price :
$35
*
At a glance
- Drugs VAX 102 (Primary) ; Influenza virus vaccine
- Indications Influenza A virus infections; Influenza virus infections
- Focus Pharmacodynamics
- Sponsors VaxInnate
- 06 Feb 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 23 Jun 2009 New trial record